Jump to content

Genedata Announces ONO Pharmaceutical Transforms High-Throughput Screening with Genedata Screener

Extending its Genedata Screener licensing, ONO accelerates drug discovery with Screener’s streamlined workflows and high speed data analysis

February 23, 2016
Basel, Switzerland

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that ONO PHARMACEUTICAL CO. LTD. (ONO) has extended its license of Genedata Screener® to capture, analyze, and manage high-throughput screening (HTS) data for ONO discovery research. Committed to developing original new drugs for patients worldwide, ONO will use Genedata Screener for HTS for streamlined workflows and accelerated data analysis.

Genedata Screener: Best-in-Class High-Speed Data Analysis
ONO PHARMACEUTICAL CO. LTD., headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company committed to creating innovative medicines such as bioactive lipids and enzyme inhibitors. Cancer therapy and supporting treatment have become strategic areas as well. Using HTS technologies to quickly conduct hundreds of thousands of pharmacological tests, ONO requires a screening data analysis and management system that can keep pace with its advanced instrumentation.

“We have been using Genedata Screener for three years and have seen that data analysis from HTS campaigns goes faster with Genedata Screener. With workflows established, it is easy to setup data analysis before experiments start and we can easily change analysis methods during and after campaigns—which minimizes our analysis time. Furthermore, Genedata Screener’s intuitive nature makes it easy for new users or users with no experience to quickly use Genedata Screener,” noted an HTS representative from ONO. “Compared to Excel-based analysis and other commercial products, we believe Genedata Screener has better processing speed and analysis capabilities.”

ONO also uses Genedata Screener to analyze data from fluorescence based assays in real-time kinetics. Access to the full time-trace at all stages of the data analysis allows identification of experimental artifacts and confirms the expected kinetics profile. Direct import of full resolution time-series data streamlines the data analysis workflow, which eliminates going back to instrument software when refining initial data aggregation. And, as time traces can be seen during quality control and hit review, false positives are quickly identified and eliminated. This improves the efficiency of data analysis in ONO discovery research, which results in cost savings, time savings, and enhanced use of internal resources.

“Leading pharmaceutical companies increasingly rely on Genedata Screener and we are proud of our successful collaboration with ONO,” said Dr. Othmar Pfannes, CEO of Genedata. “ONO’s adoption of Genedata Screener to support their HTS workflows underscores Genedata Screener’s value add to customers. Furthermore, ONO mirrors a trend among Genedata customers who broadly capitalize on their instrument technology investments by leveraging Genedata Screener for a variety of screening activities.”

About Genedata

Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube


Allison Kurz
Public Relations


The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Data analysis from HTS campaigns goes faster with Genedata Screener